Using targeted liposomes to fight harmful mycobacterial infections
Targeted pan-antibacterial liposomes to control pathogenic mycobacteria
This study is testing a new way to deliver medicine directly to tough bacteria that cause infections, which could help people with hard-to-treat illnesses use less medication while still getting better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10897712 on NIH RePORTER |
What this research studies
This research focuses on developing DectiSomes, which are specialized lipid nanoparticles designed to deliver anti-infective drugs directly to pathogenic mycobacteria. By coating these nanoparticles with receptors that specifically target mycobacterial cells, the research aims to significantly reduce the amount of medication needed to effectively combat infections. The approach is particularly relevant for treating multidrug-resistant strains of mycobacteria, which pose a significant health threat globally. The research will involve testing these targeted liposomes against various pathogenic mycobacterial species to evaluate their effectiveness in both laboratory and animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with latent or active tuberculosis or other mycobacterial infections.
Not a fit: Patients with infections caused by non-mycobacterial pathogens or those who do not have a history of antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from serious mycobacterial infections, potentially reducing the duration and dosage of antibiotic therapy.
How similar studies have performed: Previous studies have shown success with similar targeted liposome approaches in treating fungal infections, suggesting potential for success in mycobacterial infections as well.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Meagher, Richard Brian — University of Georgia
- Study coordinator: Meagher, Richard Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.